From nuts to drugs
Executive Summary
When the House Energy and Commerce Oversight Subcommittee turns its attention from salmonella-contaminated peanuts and inadequacies in the FDA system for monitoring food safety, CDER and Ranbaxy executives could be the next to feel the heat. Subcommittee Chairman Bart Stupak, D-Mich., already has an ongoing investigation into why FDA failed to remove Ranbaxy products from the market after it found GMP violations at a company plant in India in 2006 (1"The Pink Sheet," July 28, 2008, p. 27). A public review of findings from that inquiry would provide further impetus for action on the FDA Globalization Act introduced by Committee Chairman Emeritus John Dingell, D-Mich., with Stupak and Health Subcommittee Chair Frank Pallone, D-N.J. Action is needed "sooner rather than later to put the agency back on track in protecting the public from unsafe food and drugs," Stupak said Feb. 12 following a recall of all products made at the Peanut Corporation of America's Plainview, Tex., plant since its opening in 2005
You may also be interested in...
FDA Should Recall Drugs Subject To GMP Violations, Rep. Dingell Suggests
The House Energy & Commerce Committee is suggesting that it is not enough for FDA to send a warning letter to a company in violation of good manufacturing practices
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.